Skip to main content

Genome wide association and Ischaemic Stroke

Last modified: Tue, 08/18/2020 - 08:50

Genome wide association and Ischaemic Stroke

Project Data

Contact Information

Main Point of Contact:

First Name: Jane

Last Name: Maguire

Credentials: Jones St

Institutional Affiliation: University of Technology Sydney

Email: jane.maguire@uts.edu.au

Study Information

Origin of Samples/Data: Human samples and/or data

Study Description: Australian Stroke Genetics Collaborations comprises stroke patients of European ancestry who were admitted to four clinical centers across Australia (The Neurosciences Department at Gosford Hospital, Gosford; the Neurology Department at John Hunter Hospital, Newcastle; The Queen Elizabeth Hospital, Adelaide; and the Royal Perth Hospital, Perth) between 2003 and 2008. Stroke was defined by World Health Organization criteria as a sudden focal neurological deficit of vascular origin, lasting more than 24 h and confirmed by imaging, such as computerized tomography (CT) and/or magnetic resonance imaging (MRI) brain scan. Other investigative tests such as electrocardiogram, carotid doppler and trans-esophageal echocardiogram were conducted to define ischemic stroke mechanism as clinically appropriate. Cases were excluded from participation if they were aged <18 years, were diagnosed with hemorrhagic stroke or had transient ischemic attack rather than ischemic stroke or if they were unable to undergo baseline brain imaging. On the basis of these criteria, a total of 1,230 ischemic stroke cases were included in the current study. Ischemic stroke subtypes were assigned using TOAST criteria on the basis of clinical, imaging and risk factor data. ASGC controls were participants in the Hunter Community Study (HCS), a population-based cohort of individuals aged 55–85 years, predominantly of European ancestry and residing in the Hunter Region in New South Wales, Australia. Detailed recruitment methods for the HCS have been previously described. Briefly, participants were randomly selected from the New South Wales State electoral roll and were contacted by mail between 2004 and 2007. Consenting participants completed five detailed self-report questionnaires and attended the HCS data collection center, at which time a series of clinical measures were obtained. A total of 1,280 HCS participants were genotyped for the current study. Written consent obtained from all participants.

Additional Information

Grant Number (if applicable): NHMRC ID: 569257

Grant Source: National Health and Medical Research Council Project Grant

Data Information

Omic Data Available: Yes

Genotype Platform(s): Illumina

Clinical and/or other data available?: Yes

Demographic information: Age, gender, previous history of stroke, cardiovascular risk factors, baseline biochemistry, weight, height.

Phenotype(s): Stroke was defined by World Health Organization criteria as a sudden focal neurological deficit of vascular origin, lasting more than 24 h and confirmed by imaging, such as computerized tomography (CT) and/or magnetic resonance imaging (MRI) brain scan. Other investigative tests such as electrocardiogram, carotid doppler and trans-esophageal echocardiogram were conducted to define ischemic stroke mechanism as clinically appropriate.

Data on additional variables: History of NSAIDS use, Medications (yes/no) , premorbid and 3 month Functional outcome (mRs), stroke severity, subtype, TOAST, CCS.

Sample Information

Samples available for prospective analysis: No

Whole Blood: No

Saliva: No

Serum: No

Other Tissue: No

Extracted DNA: No

Extracted RNA: No

Other Extracted Biological Material: No

Approximate Number of Samples: 1200